Compliments of The Business Narrative
South Carolina Research Authority (SCRA’s) investment affiliate, SC Launch Inc., has invested in Elastrin Therapeutics Inc.
The $300,000 investment will help the company advance the development of therapeutics that reverse damaged tissue making it supple again, SCRA officials said.
The Simpsonville-based biotech startup developed this technology, which restores hardened or damaged arteries and tissues by targeting the elastic fiber and removing the calcification that causes stiffening. Initial applications include reducing hardened arteries, de-calcifying heart valves, and treating diabetes and COPD.
Elastrin became an SCRA Member Company in 2018 and received a $25,000 Academic Startup Grant. It also received a $50,000 Federal Matching Grant in 2019.
Elastrin became an SC Launch Inc. Portfolio Company in 2022 when it received this first investment of $300,000. It also received a $50,000 grant during SCRA’s pandemic funding round for startups providing Covid-19 solutions.
Elastrin recently closed a $10 million funding round, which included this investment.
It also recently announced the formation of its scientific advisory board, comprised of leading industry and university experts in cardiovascular research and clinical development.